Skip to main content

Smith + Nephew Plc Value Stock - Dividend - Research Selection

Smith and nephew

ISIN: GB0009223206 , WKN: 502816

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


The Return Trends At Smith & Nephew (LON:SN.) Look Promising

2026-02-05
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

[Latest] Global Advanced Wound Closure Market Size/Share Worth USD 32.54 Billion by 2035 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

2026-02-02
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Advanced Wound Closure Market size & share revenue was valued at approximately USD 18.47 Billion in 2025 and is expected to reach USD 19.68 Billion in 2026 and is expected to reach around USD 32.54 Billion by 2035, at a CAGR of 6.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Johnson & Johnson (Ethi

European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading; Up for Week

2026-01-30
European equities traded in the US as American depositary receipts were trending slightly lower late

Jim Cramer on Smith & Nephew: “This Group, I Do Not Like”

2026-01-22
Smith & Nephew plc (NYSE:SNN) is one of the stocks Jim Cramer recently looked at. When a caller inquired about the stock, Cramer was quick to say: They have to, they have to be sold, okay? I just, this group, I do not like. Okay, I just don’t like them because it’s commoditized, alright? I […]

Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair

2026-01-21
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has completed the acquisition of Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business with the most comprehensive suite of technologies available for rotator cuff repair (RCR). Integrity Orthopaedics is a US‑based, early‑stage commercial developer of Tendon Seam™, an innovative and disruptive biomechanical RCR system designed to significantly reduce re‑tear rates and i

SNN Boosts Shoulder Repair Portfolio With Integrity Orthopaedics Deal

2026-01-19
SNN expands its Sports Medicine portfolio with Integrity Orthopaedics, adding next-gen Tendon Seam tech to strengthen leadership in shoulder repair.

Smith & Nephew to acquire Integrity Orthopaedics for up to $450M

2026-01-14
The company has committed the cash, half of which it is paying upfront, to buy Integrity Orthopaedics for its rotator cuff repair system.

Smith & Nephew: Improving And Undervalued, But Mind The Knees

2026-01-07
Smith & Nephew (SNN) outlook: sports medicine and wound care strength vs ortho weakness. Read here for an investment analysis of SNN stock.

How Recent Analyst Moves Are Quietly Recasting The Story For S.N. Nuclearelectrica (BVB:SNN)

2026-01-07
S.N. Nuclearelectrica’s latest update keeps the fair value anchored at RON 45.55 and the discount rate steady at 12.428%, yet the price target has been lifted, which immediately raises the question of what has really changed. With revenue and broader earnings expectations effectively held in place, the move reflects a shift in how analysts are reading the existing story rather than a rewrite of the numbers that sit behind it. Stay tuned to see how you can track this evolving narrative so you...

How Recent Developments Are Shifting the Narrative for S.N. Nuclearelectrica

2025-12-22
S.N. Nuclearelectrica’s latest price target update comes against a backdrop of robust execution and shifting investor expectations, even as the fair value is held at RON 45.55 per share and the discount rate remains anchored at 12.43%. Street research on comparable healthcare and infrastructure names suggests that, when operational trends outperform and visibility on future earnings improves, markets can justify a higher trading range without altering long term valuation inputs or growth...